Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.

Rahul R AggarwalAlexander N StarodubBrian D KohGuan XingAndrew J ArmstrongMichael A Carducci

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

GS-5829 was generally tolerated but demonstrated limited efficacy and lack of dose proportional increases in plasma concentrations in patients with mCRPC.

Keyphrases

prostate cancer
open label
combination therapy
randomized controlled trial
clinical trial